Warfarin+ Vitamin K ( DrugBank: Warfarin, Vitamin K )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04246762 (ClinicalTrials.gov) | April 6, 2021 | 27/1/2020 | Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 | A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4 | Rheumatoid Arthritis | Drug: Olokizumab;Drug: Omeprazole;Drug: Caffeine;Drug: Warfarin+ Vitamin K;Drug: Midazolam | R-Pharm International, LLC | IQVIA RDS Ireland Ltd;Thermo Fisher Scientific FS | Completed | 18 Years | 70 Years | All | 16 | Phase 1 | Bulgaria;Moldova, Republic of |